Summaries for patients. What are the risks of using inhaled long-acting beta-agonist medications for the relief of asthma?
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D004334:Drug Administration Schedule; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000068759:Formoterol Fumarate; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate